---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-036645"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:37:02.033311+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Onconetix enters forbearance on $10M note; pauses ENTADFI commercialization

## Summary
- Forbearance with Veru extends April 2024 note maturity to March 31, 2025; interest at 10% on unpaid balance.
- Onconetix to pay Veru 15% of monthly cash receipts from Proteomedix licensing, Proclarix sales, and Labcorp milestones.
- Also to pay 10% of net proceeds from any financing or asset sale through March 2025.
- Altos debenture amended to extend maturity to October 31, 2024.
- Company pauses ENTADFI commercialization, terminates three employees, considers strategic alternatives.

## SEC filing metadata
- accession: 0001213900-24-036645
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea0204751-8k_oncone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-036645
- JSON: https://secwatch.observer/filing/0001213900-24-036645.json
- Plain text: https://secwatch.observer/filing/0001213900-24-036645.txt

## Key facts
- Material Agreements
  Onconetix, Inc. amended Altos Amendment with Altos Ventures (effective 2024-04-24).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Altos Ventures
  - Effective: 2024-04-24
  source text: On April 24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October 31, 2024 (the "Altos Amendment").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm
- Material Agreements
  Onconetix, Inc. entered into Forbearance Agreement with Veru Inc. (effective 2024-04-24).
  - Action: entry
  - Counterparty: Veru Inc.
  - Effective: 2024-04-24
  source text: (the “Company”) entered into an asset purchase agreement with Veru Inc., a Wisconsin corporation (“Veru”) (the “Veru APA”). Pursuant to the terms of the Veru APA, the Company agreed to provide Veru
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.